8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PHASE2CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
DRUG

Tolvaptan MR

50/80 mg capsules

DRUG

Tolvaptan IR

60/30 mg capsules

DRUG

Placebo

tablet

Trial Locations (35)

14215

Otsuka Investigational Site, Buffalo

18017

Otsuka Investigational Site, Bethlehem

19104

Otsuka Investigational Site, Philadelphia

20850

Otsuka Investigational Site, Rockville

21224

Otsuka Investigational Site, Baltimore

22908

Otsuka Investigational Site, Charlottesville

27599

Otsuka Investigational Site, Chapel Hill

29621

Otsuka Investigational Site, Anderson

30322

Otsuka Investigational Site, Atlanta

30901

Otsuka Investigational Site, Augusta

32216

Otsuka Investigational Site, Jacksonville

32935

Otsuka Investigational Site, Melbourne

35802

Otsuka Investigational Site, Huntsville

36617

Otsuka Investigational Site, Mobile

37205

Otsuka Investigational Site, Nashville

42003

Otsuka Investigational Site, Paducah

44106

Otsuka Investigational Site, Cleveland

46545

Otsuka Investigational Site, Mishawaka

48236

Otsuka Investigational Site, Detroit

55905

Otsuka Investigational Site, Rochester

61602

Otsuka Investigational Site, Peoria

66160

Otsuka Investigational Site, Kansas City

71101

Otsuka Investigational Site, Shreveport

76015

Otsuka Investigational Site, Arlington

78572

Otsuka Investigational Site, Mission

80045

Otsuka Investigational Site 2, Aurora

Otsuka Investigational Site, Aurora

80210

Otsuka Investigational Site, Denver

85284

Otsuka Investigational Site, Tempe

85381

Otsuka Investigational Site, Peoria

90025

Otsuka Investigational Site, Los Angeles

92108

Otsuka Investigational Site, San Diego

06510

Otsuka Investigational Site, New Haven

02111

Otsuka Investigational Site, Boston

08043

Otsuka Investigational Site, Voorhees Township

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT01451827 - 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Biotech Hunter | Biotech Hunter